Quick Answer
Quince Therapeutics, Inc. reported Long-Term Debt of $14.32 million for fiscal year 2024.
Quince Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2024 | $14.32M | +6.6% |
| 2023 | $13.43M | — |
| 2022 | $0.00 | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | -100.0% | -100.0% |
| June 30, 2025 | $16.99M | +22.8% | +11.3% |
| March 31, 2025 | $15.27M | +12.9% | +6.6% |
| December 31, 2024 | $14.32M | +6.6% | -3.9% |
| September 30, 2024 | $14.90M | — | +7.7% |
| June 30, 2024 | $13.83M | — | +2.3% |
| March 31, 2024 | $13.52M | — | +0.7% |
| December 31, 2023 | $13.43M | — | — |
- Quince Therapeutics, Inc. showed an increase of +6.6% in Long-Term Debt compared to the prior fiscal year.
- The most recent figure is from Quince Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: